Global law firm White & Case LLP has advised Molecular Partners AG as US law counsel on the first initial public offering by a Swiss biotech company in five years.
The price for the issuer’s offered registered shares has been fixed at CHF 22.4 per share, which implies a post-money market capitalization of approximately CHF 485 million. The shares have been listed on the SIX Swiss Exchange. J.P. Morgan is acting as Sole Global Coordinator and Joint Bookrunner, with UBS Investment Bank acting as Joint Bookrunner.
The White & Case team was led by partner Gernot Wagner with support from local partner Rebecca Emory (both Frankfurt).
For more information please speak to your local media contact.